



THE UNIVERSITY OF ARIZONA
COLLEGE OF MEDICINE TUCSON

Department
of Medicine

Medicine Grand Rounds

“Addressing a Different Approach to Heart Failure”

Speaker: **Clyde W. Yancy, MD, MSc**

University of Arizona College of Medicine – Tucson


Lecture Hall, Room 5403

1501 N. Campbell Ave., Tucson, AZ 85721

Noon – 1:00 pm | Wednesday, May 13, 2026

– A light lunch will be provided. –

About the Presenter: Clyde W. Yancy, MD, MSc is Vice Dean for Health Equity, Magerstadt Endowed Professor and Chief of Cardiology at the Northwestern University Feinberg School of Medicine, and Associate Director of the Bluhm Cardiovascular Institute in Chicago. A former President of the American Heart Association, Dr. Yancy has held key leadership roles with the National Institutes of Health, Food and Drug Administration, and the Department of Health and Human Services. His expertise spans heart failure, outcomes science, cardiovascular prevention, and health equity. He has authored more than 750 peer-reviewed publications and is consistently ranked among the top 1% most cited scientists globally. He is an elected member of the National Academy of Medicine and other leading professional societies.



[READ MORE >>>](#)

Livestream link: <https://streaming.biocom.arizona.edu/streaming/30996/event>

Zoom link: <https://arizona.zoom.us/j/84513372985>

Accreditation Statement: The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The college designates this live activity for a maximum of *1 AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement: All Faculty, CME Planning Committee Members, and the CME Office Reviewers have disclosed that they have no financial relationships with ineligible companies that would constitute a conflict of interest concerning this CME activity.

Learning Objectives:

1. Review the history
2. Establish contemporary therapy for HFrEF and HFpEF
3. Identify residual risk
4. Explore the potential for more substantial prevention
5. Consider new biology further transforming care and management
6. Anticipate breakthrough science capable of reversing the disease

For questions or accommodations that may be necessary, please contact the Office of the Chair, 520-626-7174.